NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

被引：0
作者：
Munechika Enjoji
Kazuyuki Machida
Motoyuki Kohjima
Masaki Kato
Kazuhiro Kotoh
Kazuhisa Matsunaga
Manabu Nakashima
Makoto Nakamuta
机构：
[1] Fukuoka University,Faculty of Pharmaceutical Sciences
[2] National Hospital Organization,Clinical Research Center, Kyushu Medical Center
[3] National Hospital Organization,Department of Gastroenterology, Kyushu Medical Center
[4] Kyushu University,Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences
来源：
Lipids in Health and Disease | / 9卷
关键词：
Ezetimibe; Nonalcoholic Fatty Liver Disease; NAFLD Patient; Ursodiol; Ezetimibe Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
[31]   The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study [J].
Erkan, Gulbanu ;
Sayin, Irmak ;
Polat, Fatma Betul ;
Corakci, Ahmet ;
Atac, Gokce Kaan ;
Degertekin, Halil .
TURKISH JOURNAL OF GASTROENTEROLOGY, 2014, 25 :63-68
[32]   Therapeutic response to ezetimibe in C57BL/6 mice is mediated by changes in NPC1L1, ABCG5 and ABCG8 expression in the enterocyte [J].
Caamano, Jose M. ;
Saavedra, Nicolas ;
Wulff, Cristian ;
Salazar, Luis A. .
INTERNATIONAL JOURNAL OF MORPHOLOGY, 2012, 30 (02) :531-540
[33]   Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population [J].
Cui, Yuliang ;
Liu, Jing ;
Shi, Haiyan ;
Hu, Wenmei ;
Song, Li ;
Zhao, Qing .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (05)
[34]   Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1 [J].
Yin, Yue-Hua ;
Sang, Li-Xuan ;
Chang, Bing .
WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (48) :6235-6238
[35]   Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice [J].
Bae, Jin-Sik ;
Park, Jong-Min ;
Lee, Junghoon ;
Oh, Byung-Chul ;
Jang, Sang-Ho ;
Lee, Yun Bin ;
Han, Young-Min ;
Ock, Chan-Young ;
Cha, Ji-Young ;
Hahm, Ki-Baik .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 66 :32-44
[36]   Epidemiology of nonalcoholic fatty liver disease in non-obese populations: Meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles [J].
Zou, Zi Yuan ;
Wong, Vincent Wai-Sun ;
Fan, Jian Gao .
JOURNAL OF DIGESTIVE DISEASES, 2020, 21 (07) :372-384
[37]   The Risk of Type 2 Diabetes and Coronary Artery Disease in Non-obese Patients With Non-alcoholic Fatty Liver Disease: A Cohort Study [J].
Dai, Wen ;
Zhang, Ziyu ;
Zhao, Shuiping .
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
[38]   Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease [J].
Stergios A. Polyzos ;
Athanasios D. Anastasilakis ;
Jannis Kountouras ;
Polyzois Makras ;
Athanasios Papatheodorou ;
Panagiotis Kokkoris ;
Grigorios T. Sakellariou ;
Evangelos Terpos .
Journal of Bone and Mineral Metabolism, 2016, 34 :447-456
[39]   Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease [J].
Polyzos, Stergios A. ;
Anastasilakis, Athanasios D. ;
Kountouras, Jannis ;
Makras, Polyzois ;
Papatheodorou, Athanasios ;
Kokkoris, Panagiotis ;
Sakellariou, Grigorios T. ;
Terpos, Evangelos .
JOURNAL OF BONE AND MINERAL METABOLISM, 2016, 34 (04) :447-456
[40]   Apoptosis signal-regulating kinase-1 as a therapeutic target in nonalcoholic fatty liver disease [J].
Kefala, Georgia ;
Tziomalos, Konstantinos .
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (03) :189-191
12345